Characterization of joint disease in mucopolysaccharidosis type I mice
- PMID: 23786352
- PMCID: PMC3781776
- DOI: 10.1111/iep.12033
Characterization of joint disease in mucopolysaccharidosis type I mice
Abstract
Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by mutations in enzymes that degrade glycosaminoglycans (GAGs). Joint disease is present in most forms of MPS, including MPS I. This work aimed to describe the joint disease progression in the murine model of MPS I. Normal (wild-type) and MPS I mice were sacrificed at different time points (from 2 to 12 months). The knee joints were collected, and haematoxylin-eosin staining was used to evaluate the articular architecture. Safranin-O and Sirius Red staining was used to analyse the proteoglycan and collagen content. Additionally, we analysed the expression of the matrix-degrading metalloproteinases (MMPs), MMP-2 and MMP-9, using immunohistochemistry. We observed progressive joint alterations from 6 months, including the presence of synovial inflammatory infiltrate, the destruction and thickening of the cartilage extracellular matrix, as well as proteoglycan and collagen depletion. Furthermore, we observed an increase in the expression of MMP-2 and MMP-9, which could conceivably explain the degenerative changes. Our results suggest that the joint disease in MPS I mice may be caused by a degenerative process due to increase in proteases expression, leading to loss of collagen and proteoglycans. These results may guide the development of ancillary therapies for joint disease in MPS I.
Keywords: alpha-L-iduronidase; joint disease; matrix metalloproteinases; mucopolysaccharidoses type I.
© 2013 The Authors. International Journal of Experimental Pathology © 2013 International Journal of Experimental Pathology.
Figures




Similar articles
-
Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.Reprod Fertil Dev. 2020 Feb;32(3):304-312. doi: 10.1071/RD19144. Reprod Fertil Dev. 2020. PMID: 31679559
-
Biomechanical and histological characterization of MPS I mice femurs.Acta Histochem. 2021 Feb;123(2):151678. doi: 10.1016/j.acthis.2020.151678. Epub 2021 Jan 9. Acta Histochem. 2021. PMID: 33434858
-
Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in mucopolysaccharidosis I.Mol Genet Metab. 2015 Feb;114(2):146-55. doi: 10.1016/j.ymgme.2014.09.012. Epub 2014 Oct 7. Mol Genet Metab. 2015. PMID: 25410057
-
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.Cells. 2020 Aug 5;9(8):1838. doi: 10.3390/cells9081838. Cells. 2020. PMID: 32764324 Free PMC article. Review.
-
Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.Osteoarthritis Cartilage. 2013 Dec;21(12):1813-23. doi: 10.1016/j.joca.2013.08.001. Epub 2013 Aug 13. Osteoarthritis Cartilage. 2013. PMID: 23954699 Review.
Cited by
-
Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.Cells. 2020 Apr 15;9(4):979. doi: 10.3390/cells9040979. Cells. 2020. PMID: 32326609 Free PMC article. Review.
-
Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.Gene Ther. 2020 Feb;27(1-2):74-84. doi: 10.1038/s41434-019-0113-4. Epub 2019 Dec 11. Gene Ther. 2020. PMID: 31827259
-
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Seeking into Cell-Free Therapies for Bone-Affected Lysosomal Storage Disorders.Int J Mol Sci. 2025 Jul 4;26(13):6448. doi: 10.3390/ijms26136448. Int J Mol Sci. 2025. PMID: 40650223 Free PMC article. Review.
-
The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.PLoS One. 2015 Jul 6;10(7):e0131662. doi: 10.1371/journal.pone.0131662. eCollection 2015. PLoS One. 2015. PMID: 26147524 Free PMC article.
-
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.Bone. 2022 Jan;154:116237. doi: 10.1016/j.bone.2021.116237. Epub 2021 Oct 22. Bone. 2022. PMID: 34695616 Free PMC article.
References
-
- Baldo G, Kretzmann NA, Tieppo J, et al. Bone marrow cells reduce collagen deposition in the rat model of common bile duct ligation. Cell. Sci. Ther. 2011b;2:1–6.
-
- Clarke LA, Russell CS, Pownall S, et al. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum. Mol. Genet. 1997;6:503–511. - PubMed
-
- Giugliani R, Federhen A, Muñoz Rojas MV, et al. Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts. Rev. Assoc. Med. Bras. 2010;56:271–277. [Article in Portuguese] - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous